Tactiva Therapeutics, a Buffalo, NY-based development stage immuno-oncology company with a unique approach to adoptive T-cell therapy, secured a $35m Series A financing and closed on the first tranche of the financing.
The round was led by Panacea Healthcare Partners with participation from Vi Ventures and Efung Capital.
The company intends to use the funds to advance the clinical development of its dual enhanced adoptive cell therapy (DEACT™) platform for the treatment of Multiple Myeloma and several solid tumor type cancer indications.
Led by Matthew Colpoys, CEO, Tactiva Therapeutics is a development stage immuno-oncology company with a unique approach to adoptive T-cell therapy. The company’s dual enhanced adoptive cell therapy (DEACT™) platform consists of engineered CD4/CD8 cells which generate a durable supply of CD4 cells with direct anti-tumor activity as well as sustained helper function to CD8 T cell derived TCR-transduced effector T cells.
Tactiva Therapeutics has also received funding from the UB Center for Advanced Technology in Big Data and Health Sciences, which supported a collaboration that aids the company’s discovery efforts.
The company, which is located at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences on the Buffalo Niagara Medical Campus, is also a partner with the university’s Buffalo Institute for Genomics and Data Analytics (BIG).